Structure modeling of the chemokine receptor CCR5: implications for ligand binding and selectivity
- PMID: 12496074
- PMCID: PMC1302382
- DOI: 10.1016/S0006-3495(02)75307-1
Structure modeling of the chemokine receptor CCR5: implications for ligand binding and selectivity
Abstract
The G-protein coupled receptor CCR5 is the main co-receptor for macrophage-tropic HIV-1 strains. I have built a structural model of the chemokine receptor CCR5 and used it to explain the binding and selectivity of the antagonist TAK779. Models of the extracellular (EC) domains of CCR5 have been constructed and used to rationalize current biological data on the binding of HIV-1 and chemokines. Residues spanning the transmembrane region of CCR5 have been modeled after rhodopsin, and their functional significance examined using the evolutionary trace method. The receptor cavity shares six residues with CC-chemokine receptors CCR1 through CCR4, while seven residues are unique to CCR5. The contribution of these residues to ligand binding and selectivity is tested by molecular docking simulations of TAK779 to CCR1, CCR2, and CCR5. TAK779 binds to CCR5 in the cavity formed by helices 1, 2, 3, and 7 with additional interactions with helices 5 and 6. TAK779 did not dock to either CCR1 or CCR2. The results are consistent with current site-directed mutagenesis data and with the observed selectivity of TAK779 for CCR5 over CCR1 and CCR2. The specific residues responsible for the observed selectivity are identified. The four EC regions of CCR5 have been modeled using constrained simulated annealing simulations. Applied dihedral angle constraints are representative of the secondary structure propensities of these regions. Tertiary interactions, in the form of distance constraints, are generated from available epitope mapping data. Analysis of the 250 simulated structures provides new insights to the design of experiments aimed at determining residue-residue contacts across the EC domains and for mapping CC-chemokines on the surface of the EC domains.
Similar articles
-
Building three-dimensional structures of HIV-1 coreceptor CCR5 and its interaction with antagonist TAK779 by comparative molecular modeling.Acta Pharmacol Sin. 2000 Jun;21(6):521-8. Acta Pharmacol Sin. 2000. PMID: 11360686
-
Chapter 12. The use of receptor homology modeling to facilitate the design of selective chemokine receptor antagonists.Methods Enzymol. 2009;461:249-79. doi: 10.1016/S0076-6879(09)05412-3. Methods Enzymol. 2009. PMID: 19480923
-
Elucidation of binding sites of dual antagonists in the human chemokine receptors CCR2 and CCR5.Mol Pharmacol. 2009 Jun;75(6):1325-36. doi: 10.1124/mol.108.053470. Epub 2009 Mar 18. Mol Pharmacol. 2009. PMID: 19297521
-
Structural Analysis of Chemokine Receptor-Ligand Interactions.J Med Chem. 2017 Jun 22;60(12):4735-4779. doi: 10.1021/acs.jmedchem.6b01309. Epub 2017 Mar 10. J Med Chem. 2017. PMID: 28165741 Free PMC article. Review.
-
HIV co-receptor CCR5: structure and interactions with inhibitors.Infect Disord Drug Targets. 2009 Jun;9(3):279-88. doi: 10.2174/1871526510909030279. Infect Disord Drug Targets. 2009. PMID: 19519482 Review.
Cited by
-
Adaptive Gene Loss? Tracing Back the Pseudogenization of the Rabbit CCL8 Chemokine.J Mol Evol. 2016 Aug;83(1-2):12-25. doi: 10.1007/s00239-016-9747-7. Epub 2016 Jun 15. J Mol Evol. 2016. PMID: 27306379
-
Comparative docking study of anibamine as the first natural product CCR5 antagonist in CCR5 homology models.J Chem Inf Model. 2009 Jan;49(1):120-32. doi: 10.1021/ci800356a. J Chem Inf Model. 2009. PMID: 19166361 Free PMC article.
-
Estimation of 2Nes from temporal allele frequency data.Genetics. 2008 May;179(1):497-502. doi: 10.1534/genetics.107.085019. Genetics. 2008. PMID: 18493066 Free PMC article.
-
Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.Antimicrob Agents Chemother. 2005 Nov;49(11):4721-32. doi: 10.1128/AAC.49.11.4721-4732.2005. Antimicrob Agents Chemother. 2005. PMID: 16251317 Free PMC article.
-
The differential sensitivity of human and rhesus macaque CCR5 to small-molecule inhibitors of human immunodeficiency virus type 1 entry is explained by a single amino acid difference and suggests a mechanism of action for these inhibitors.J Virol. 2004 Apr;78(8):4134-44. doi: 10.1128/jvi.78.8.4134-4144.2004. J Virol. 2004. PMID: 15047829 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases